Corona Remedies IPO

About Corona Remedies IPO

The Corona Remedies IPO opens on Monday, Dec 8, 2025 and closes on Wednesday, Dec 10, 2025. The allotment of shares will take place on Thursday, Dec 11, 2025 . The credit of shares to the demat account will take place on Friday, Dec 12, 2025. The initiation of refunds will take place on Friday, Dec 12, 2025. The listing of shares will take place on Monday, Dec 15, 2025.

Corona Remedies IPO price band is set at ₹1008 to ₹1062 per share. The lot size for an application is 14 Shares. The minimum amount of investment required by a retail is ₹14,868 (14 shares) (based on upper price). The lot size investment for sNII is 14 lots (196 shares), amounting to ₹2,08,152, and for bNII, it is 68 lots (952 shares), amounting to ₹10,11,024.

The offer consists of an offer for sale component. The offer for sale portion includes 61,71,101 shares (aggregating up to ₹655.37 crores). Hence the total number of shares and aggregate amount is 61,71,101 shares (aggregating up to ₹655.37 crores).

Corona Remedies is an India-focused branded pharmaceutical formulation company engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabeto, pain management, urology and other therapeutic areas.

Objectives of Corona Remedies IPO

• To achieve the benefits of listing the Equity Shares on the Stock Exchanges and for the Offer for Sale of 61,71,101 shares (aggregating up to ₹655.37 crores).

• Enhance the company’s visibility and brand and provide liquidity to its existing Shareholders.

• To provide a public market for the Equity Shares in India.

Industry Outlook

According to the Industry Report, the Indian domestic formulations market (consumption) is expected to grow at a CAGR of 8–9% between financial years 2024 and 2029, to approximately ₹3,00,000–3,20,000 crores in financial year 2029, aided by strong demand on account of the rising incidence of chronic diseases, increased awareness, and access to quality healthcare (Source: Industry Report). Going ahead , oncology, anti-diabetic, women’s health and CNS therapy segments are expected to record stronger growth over the next five years from Calendar Year 2024 as compared with other therapeutic segments. In addition, India is ranked fourth among the selected countries within the CRISIL Intelligence Report for lifetime infertility prevalence. Based on these and other factors, within the domestic formulation market, the gynecological therapeutic area is expected to grow at a CAGR of 8.50-9.50%, the cardiovascular and anti-diabetic therapeutic areas are expected to grow at a CAGR of 10.00-11.00%, and urology is expected to grow at a CAGR of 9.00- 10.00%, each between the Financial Years 2025 and 2030.

Corona Remedies Company Information

Corona Remedies is the fastest growing company among the top 30 companies in the Indian Pharmaceutical Market (IPM) in terms of domestic sales in the IPM, between MAT June 2024 and MAT June 2025. Their differentiated strategy of focusing on the "middle of the pyramid", where they focus on specialist doctors, has driven their growth to outpace overall prescription growth in the IPM over MAT December 2021 to 2024 (Source: Industry Report). Their diversified product portfolio comprises 71 brands catering to a range of therapeutic areas such as women’s healthcare, cardio-diabeto, pain management, urology and others/multispecialty pharmaceuticals (comprising vitamins/minerals/nutrition (“VMN”), gastrointestinal and respiratory), as of June 30, 2025.

Strengths of Corona Remedies IPO

• Second fastest-growing company within the top 30 pharmaceutical companies in the Indian pharmaceutical market.
• Demonstrated capabilities of building a diversified portfolio.
• Pan-India sales network and marketing strategy focused on the “middle of the pyramid” target market.
• They have been able to achieve leadership positions for several brands.
• Focused growth within the chronic and sub-chronic segments.
• Quality and current good manufacturing practices-focused manufacturing facilities.
• Qualified, experienced and entrepreneurial management team supported by marquee investors.

Risks of Corona Remedies IPO

• Possibility of products in the therapeutic areas of women’s healthcare, cardio-diabeto, and pain management not performing as expected.
• They derive a significant majority of their revenue from operations within India. Any adverse situation in India will affect their business
• They are exposed to government price controls, which could negatively affect their results of operations.
• A significant portion of their domestic sales are concentrated in the states of Gujarat, Maharashtra, Chhattisgarh, Goa and Madhya Pradesh.
• Dependency on third-party suppliers to procure raw materials and finished goods.
• Inability to obtain trademarks for their products and brands or protect other proprietary information.
• A highly competitive industry.
• Reliance on a field force of 2,671 medical representatives.
• Subject to extensive government regulation in India.

Source: All the financial information for listed industry peer mentioned above is on a consolidated basis (except Abbott India Limited) and is sourced from the filings made with stock exchanges available on www.bseindia.com for the Financial Year ending March 31, 2025. Source for Corona Remedies: Based on the Restated Consolidated Financial Statements for the year ended March 31, 2025. Notes: 1. P/E Ratio has been computed based on the closing market price of equity shares on November 28, 2025, divided by the Diluted EPS. 2. Return on net worth is the restated profit attributable to owners of the Company divided by the net worth at the end of the period / year. 3. Net asset value per equity share as at a period/year represents net worth as of the end of the period/year divided by the weighted average outstanding equity shares considered for EPS as the end of the period/year.

Anchor Investor Information

The Anchor Investor Bidding Date shall be Friday, December 5, 2025

IPO Registrar and Book Running Lead Managers

Book running lead managers:

• JM Financial Limited
  
• IIFL Capital Services Limited
  
• Kotak Mahindra Capital Company Limited
  

Registrar for the IPO is Bigshare Services Private Limited

Corona Remedies Business Model

The company earns its revenue through developing, manufacturing, and marketing products in women’s healthcare, cardio-diabeto, pain management, urology, and other therapeutic areas.

Corona Remedies Growth Trajectory

The company’s Total Income was ₹1202.353 crores for FY 2025 compared to ₹1020.931 crores for FY2024.

The company’s Profit After Tax was ₹149.434 crores for FY 2025 compared to ₹90.503 crores for FY2024.

EBITDA for the company was ₹245.913 crores for FY 2025 compared to ₹161.190 crores for FY2024.

Corona Remedies Market Position

Their pan-India marketing and distribution network was supported by a growing field force of 2,671 medical representatives across 22 states in India (as of June 30, 2025). Their pres ence spans over 20 countries, including the United Arab Emirates, Uzbekistan, the Philippines, Kenya, Cyprus, and others, where they employ a calibrated and market-specific approach that takes into account regulatory landscapes, market size, competitive environments, and product demand in each region.

According to the Industry Report, they are the second fastest-growing company among the top 30 companies in the Indian Pharmaceutical Market (IPM) in terms of domestic sales between MAT December 2021 and MAT December 2024.

During Financial Year 2024, they acquired the Myoril brand from Sanofi Healthcare India Private Limited (Sanofi), which has strengthened their pain management portfolio and allowed them to expand their presence in this critical therapeutic area.

As of 31 March 2025, the company’s Total Income, Profit After Tax, and EBITDA were ₹1202.353 crores, ₹149.434 crores, and ₹245.913 crores, respectively.

How to apply for Corona Remedies IPO?

• Step 1: Log in to your Kotak Securities Demat account - Log in to your Demat account to access IPO investments. Next, select the current IPO section.
• Step 2: Specify IPO details - Enter the number of lots and the price you wish to apply for.
• Step 3: Enter UPI ID - After entering your UPI ID, click submit. This will place your bid with the exchange.
• Step 4: Mandate Notification - Your UPI app will receive a mandate notification to block funds.
• Step 5: Approve Request - Your funds will be blocked once you approve the mandate request on your UPI.